CA-SCIENTIST.COM
18.6.2024 13:56:30 CEST | Business Wire | Press release
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that LIDE Biotech has successfully completed VERIF.i® on-site assessments at two of its China-based facilities—Shanghai and Xi’an. VERIF.i is Scientist.com’s on-site pre-assessment program that helps suppliers of regulated services demonstrate the quality and standards of their laboratories to both existing and prospective clients.
LIDE is an award-winning, translational medicine contract research organization (CRO) with over a decade of experience delivering preclinical drug evaluation services globally. In addition to offering innovations in oncology translational research and immune-oncology, LIDE has a collection of over 2,000 patient derived xenograft (PDX) models covering 50+ cancer types, of which 200+ are special drug resistant and/or genetically altered. The company owns AAALAC accredited SPF level Animal Centers, safety level 2 laboratories and world-class, state of the art equipment.
“We’ve adopted the highest global operational standards at LIDE, ensuring our facilities and processes not only meet but surpass industry expectations,” stated Dr. Danyi Wen, President and CEO of LIDE Biotech. “VERIF.i is one more way to demonstrate our commitment to quality and compliance to our biotech and pharmaceutical clients globally.”
VERIF.i provides LIDE Biotech and other suppliers of regulated research services, including human biospecimen acquisition, animal studies and chemistry, manufacturing and controls (CMC) services, the opportunity to proactively communicate the quality and capabilities of their laboratories against pre-defined criteria developed specifically for the biopharma industry. Independent, third-party auditors carry out on-site inspections, the results of which can be shared with clients or used to improve lab operations.
“On-site assessments of laboratories have always been difficult to complete due to high costs and intensive resource and time requirements,” stated Matt McLoughlin, SVP of Categories and Compliance at Scientist.com. “VERIF.i provides a new and viable solution for marketplace sellers and buyers alike. It enables a high-quality supplier like LIDE to differentiate itself from its peers by sharing information about its facilities, personnel and processes. At the same time, it eliminates redundant work and ultimately saves both buyers and sellers time and money."
VERIF.i is an expansion of Scientist.com’s award-winning COMPLi® solution. For more information visit https://www.scientist.com/verifi/
About LIDE Biotech
LIDE biotech is committed to accelerating translation from pre-clinical to clinical for our clients. Our robust database of over 2000+ PDX, CDX, and cell line models is an industry-leading resource. Additionally, LIDE provides proprietary kits (small sample K-cell collection, conditional cell reprogramming, MiniPDX and IO-FIVE assays) that help clients streamline their studies. Most importantly, our hospital collaborations offer clients an unparalleled translational platform to leverage in their drug R&D journey. Our CRO services can be custom tailored or leveraged with out-of-the-box solutions, including in vitro and in vivo studies, 3D and organoid approaches, all supplemented with in-house bioinformatics and a parallel immuno-oncology platform.
Visit www.lidebiotech.com to learn more and follow updates on the LIDE Biotech LinkedIn page.
About Scientist.com
Scientist.com is a privately held San Diego-based company on a mission to make it faster and cheaper to discover new medicines. At its heart is an AI-powered marketplace that helps drug researchers use innovative technologies to rapidly translate their ideas into actionable data. Through Scientist.com, scientists communicate directly with research experts at over 5,000 global laboratories to design and execute complex research experiments. Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618429370/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom